ArticleBMC medical imaging2025
Reduction of metallic artifacts from the novel leadless pacemaker using single-energy metal artifact reduction algorithm in coronary CT angiography.
Article in BMC medical imaging, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
objectiveTo evaluate the efficacy of single-energy metal artifact reduction (SEMAR) algorithm in removing metallic artifacts for patients with novel leadless pacemakers (PMs) compared to those with conventional transvenous PMs.
methods30 patients with transvenous PMs and 30 patients with leadless PMs having coronary CT angiography (CCTA) were included. Images were reconstructed using two methods: a conventional hybrid-iterative reconstruction (HIR) algorithm separately, and the HIR combined with SEMAR algorithm. The artifact index (AI) was calculated for both datasets to quantitatively assess the artifact reduction. Two senior radiologists independently scored the artifact extent and diagnostic confidence of surrounding tissues. The position of artifacts-impaired tissues was also visually evaluated as follows: non-impaired, impaired, and equivocal. The study was ethics committee-approved.
resultsThe leadless PM
conclusionsSEMAR provides effective reduction of metallic artifacts from both types of cardiac PMs. The artifact-impaired tissues are fewer on leadless PMs, resulting in an enhanced diagnostic confidence in the surrounding tissues.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.